These results are in accordance with the previous reports showing homogeneous distribution of KRAS mutation status in retrospectively studied, paraffin-embedded tumor samples from NSCLC patients subjected to surgical treatment (Alsdorf et al. 2013; Li et al. 1994). The gene discussed is KRAS; the disease is neoplasm.